{
  "parsed": [
    {
      "model": "claude",
      "raw": "\n\n\u2500\u2500\u2500 SECTION 1: DECOMPOSITION \u2500\u2500\u2500\n\n**Sub-questions:**\n1. **What quantitative relationship links metformin concentration \u2192 Complex I inhibition fraction \u2192 AMP:ATP ratio \u2192 AMPK activation?** (The dose-response cascade)\n2. **Why does AMPK activation saturate at low Complex I inhibition while toxicity requires high inhibition?** (Signal amplification asymmetry)\n3. **How do tissue-specific OCT transporter density and mitochondrial spare respiratory capacity (SRC) jointly determine the therapeutic-toxic boundary?**\n4. **What is the kinetic transition point where compensatory glycolysis fails to maintain ATP, triggering lactic acidosis?**\n\n**Key variables:** Plasma [Met] \u2192 intramitochondrial [Met] (OCT-dependent) \u2192 Complex I inhibition fraction \u2192 NADH/NAD+ \u2192 AMP:ATP \u2192 AMPK activation vs. PMF collapse. SRC acts as the buffer variable.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\n**CLAIM 1:** The therapeutic-toxic divergence arises from a signal amplification mismatch: AMPK's cooperative AMP sensing (effective Hill coefficient ~2\u20133 at \u03b3-subunit) produces near-maximal activation at 20\u201330% Complex I inhibition, while ATP depletion sufficient for cellular failure requires >50\u201360% sustained inhibition.\n**TYPE:** 1\n**CONFIDENCE:** 0.88\n**MECHANISM:** AMPK \u03b3-subunit binds AMP with positive cooperativity (Kd ~1\u20135 \u00b5M AMP), amplifying small energetic perturbations into full kinase activation, whereas ATP synthesis decline scales linearly with Complex I block until SRC is exhausted.\n**FALSIFIABLE BY:** Demonstration that AMPK activation in hepatocytes requires >50% Complex I inhibition, or that AMPK \u03b3-subunit AMP binding is non-cooperative (Hill ~1).\n\n**CLAIM 2:** Tissue vulnerability follows the product of OCT-mediated uptake rate and inverse SRC: kidney cortex (OCT2-high, SRC ~20\u201330%) > liver (OCT1-high, SRC ~40\u201350%) > skeletal muscle (OCT3-low, SRC ~60\u201370%). Lactic acidosis emerges specifically when hepatic lactate clearance fails due to liver mitochondrial compromise, not primarily from peripheral lactate overproduction.\n**TYPE:** 1\n**CONFIDENCE:** 0.85\n**MECHANISM:** Liver is both the therapeutic target (gluconeogenesis suppression via AMPK/reduced ATP) and the critical toxicity node\u2014when hepatic SRC is exceeded, lactate clearance via gluconeogenesis and oxidation ceases, causing systemic lactate accumulation.\n**FALSIFIABLE BY:** Clinical MALA cases showing preserved hepatic lactate clearance with toxicity driven purely by peripheral overproduction; or renal toxicity preceding hepatic dysfunction in OCT1-knockout models.\n\n**CLAIM 3:** The ~50% Complex I inhibition threshold identified as singular is mechanistically real and corresponds to the SRC exhaustion point in hepatocytes: below this, oxidative phosphorylation compensates via increased electron flux through remaining Complex I and Complex II; above this, PMF drops below the threshold for ATP synthase operation (~120 mV).\n**TYPE:** 2\n**CONFIDENCE:** 0.78\n**MECHANISM:** Hepatocyte SRC of ~40\u201350% means that up to ~40\u201350% Complex I loss is buffered; beyond this, mitochondrial membrane potential collapses non-linearly, forcing complete glycolytic dependence.\n**FALSIFIABLE BY:** Measurement of hepatocyte \u0394\u03a8m showing linear (not threshold) decline with Complex I inhibition, or SRC measurements substantially different from 40\u201350%.\n\n**CLAIM 4:** Metformin's Complex I inhibition is functionally reversible at therapeutic concentrations (Kd ~20 mM for the IQ site) but becomes kinetically trapped at supratherapeutic intramitochondrial concentrations (>5 mM) due to membrane-potential-driven accumulation and slow off-rate in depolarized mitochondria.\n**TYPE:** 2\n**CONFIDENCE:** 0.72\n**MECHANISM:** Metformin, a cation, accumulates in the matrix driven by \u0394\u03a8m; when \u0394\u03a8m drops from inhibition, the thermodynamic driving force for efflux disappears, trapping metformin and creating a positive feedback loop.\n**FALSIFIABLE BY:** Evidence that metformin efflux is \u0394\u03a8m-independent, or that Complex I inhibition reverses equally fast at high and low [Met].\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS \u2500\u2500\u2500\n\n- Precise intramitochondrial [Met] at therapeutic vs. toxic plasma levels in human hepatocytes *in vivo* (most data from rodent or isolated mitochondria).\n- Whether Complex I inhibition is the sole or even dominant mechanism at therapeutic doses\u2014glycerol-3-phosphate dehydrogenase inhibition and lysosomal effects may contribute independently.\n- Actual Hill coefficient for",
      "claims": [
        {
          "statement": "1:** The therapeutic-toxic divergence arises from a signal amplification mismatch: AMPK's cooperative AMP sensing (effective Hill coefficient ~2\u20133 at \u03b3-subunit) produces near-maximal activation at 20\u201330% Complex I inhibition, while ATP depletion sufficient for cellular failure requires >50\u201360% sustained inhibition.",
          "type": 1,
          "confidence": 0.88,
          "mechanism": "AMPK \u03b3-subunit binds AMP with positive cooperativity (Kd ~1\u20135 \u00b5M AMP), amplifying small energetic perturbations into full kinase activation, whereas ATP synthesis decline scales linearly with Complex I block until SRC is exhausted.",
          "falsifiable_by": "Demonstration that AMPK activation in hepatocytes requires >50% Complex I inhibition, or that AMPK \u03b3-subunit AMP binding is non-cooperative (Hill ~1)."
        },
        {
          "statement": "2:** Tissue vulnerability follows the product of OCT-mediated uptake rate and inverse SRC: kidney cortex (OCT2-high, SRC ~20\u201330%) > liver (OCT1-high, SRC ~40\u201350%) > skeletal muscle (OCT3-low, SRC ~60\u201370%). Lactic acidosis emerges specifically when hepatic lactate clearance fails due to liver mitochondrial compromise, not primarily from peripheral lactate overproduction.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Liver is both the therapeutic target (gluconeogenesis suppression via AMPK/reduced ATP) and the critical toxicity node\u2014when hepatic SRC is exceeded, lactate clearance via gluconeogenesis and oxidation ceases, causing systemic lactate accumulation.",
          "falsifiable_by": "Clinical MALA cases showing preserved hepatic lactate clearance with toxicity driven purely by peripheral overproduction; or renal toxicity preceding hepatic dysfunction in OCT1-knockout models."
        },
        {
          "statement": "3:** The ~50% Complex I inhibition threshold identified as singular is mechanistically real and corresponds to the SRC exhaustion point in hepatocytes: below this, oxidative phosphorylation compensates via increased electron flux through remaining Complex I and Complex II; above this, PMF drops below the threshold for ATP synthase operation (~120 mV).",
          "type": 2,
          "confidence": 0.78,
          "mechanism": "Hepatocyte SRC of ~40\u201350% means that up to ~40\u201350% Complex I loss is buffered; beyond this, mitochondrial membrane potential collapses non-linearly, forcing complete glycolytic dependence.",
          "falsifiable_by": "Measurement of hepatocyte \u0394\u03a8m showing linear (not threshold) decline with Complex I inhibition, or SRC measurements substantially different from 40\u201350%."
        },
        {
          "statement": "4:** Metformin's Complex I inhibition is functionally reversible at therapeutic concentrations (Kd ~20 mM for the IQ site) but becomes kinetically trapped at supratherapeutic intramitochondrial concentrations (>5 mM) due to membrane-potential-driven accumulation and slow off-rate in depolarized mitochondria.",
          "type": 2,
          "confidence": 0.72,
          "mechanism": "Metformin, a cation, accumulates in the matrix driven by \u0394\u03a8m; when \u0394\u03a8m drops from inhibition, the thermodynamic driving force for efflux disappears, trapping metformin and creating a positive feedback loop.",
          "falsifiable_by": "Evidence that metformin efflux is \u0394\u03a8m-independent, or that Complex I inhibition reverses equally fast at high and low [Met]. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "mistral",
      "raw": "---\n**SECTION 1: DECOMPOSITION**\n1. **AMPK activation vs. Complex I inhibition thresholds**: How do the dose-response curves for AMPK activation (therapeutic) and Complex I inhibition (toxic) diverge, and what determines their respective Hill coefficients?\n2. **Mitochondrial reserve as a vulnerability modulator**: How does tissue-specific mitochondrial spare capacity (e.g., liver vs. kidney) interact with OCT transporter density to dictate toxicity thresholds?\n3. **Redox and adenylate buffering at supratherapeutic doses**: At what intramitochondrial [Met] does Complex I inhibition become irreversible, and how do NADH/NAD\u207a imbalance and ATP depletion kinetics drive lactic acidosis?\n4. **Kinetic trapping of Complex I**: Is the shift from reversible to irreversible inhibition a function of [Met] exceeding IC\u2085\u2080, or does it depend on exposure duration and redox state?\n\nKey variables: [Met] (plasma vs. mitochondrial), OCT1/2 expression, mitochondrial reserve (spare capacity, GSH, adenylate kinase), AMPK \u03b3-subunit cooperativity, Complex I Hill coefficient, NADH/NAD\u207a ratio, PMF collapse kinetics.\n\n---\n\n**SECTION 2: CLAIMS**\n\n**CLAIM 1**: The therapeutic window (1\u201310 \u00b5M plasma) is defined by AMPK\u2019s hypersensitive activation (20\u201340% \u0394AMP:ATP) at sub-toxic Complex I inhibition (~20\u201340% block), while lactic acidosis requires >50% irreversible Complex I inhibition (>5 mM mitochondrial [Met]).\n**TYPE**: 1 (converged + mechanistic)\n**CONFIDENCE**: 0.88\n**MECHANISM**: AMPK\u2019s \u03b3-subunit binds AMP cooperatively (Hill coefficient >1), amplifying sensitivity to mild energetic stress, whereas Complex I inhibition follows non-cooperative kinetics (Hill coefficient ~1), requiring higher [Met] for toxicity.\n**FALSIFIABLE BY**: Evidence that AMPK activation requires >50% Complex I block, or that Hill coefficients for AMPK and Complex I are identical.\n\n**CLAIM 2**: Tissue-specific toxicity is determined by the product of OCT transporter density and mitochondrial reserve, with kidney (OCT2-high, low reserve) > liver (OCT1-high, moderate reserve) > muscle (low OCT, high reserve) vulnerability.\n**TYPE**: 1 (converged)\n**CONFIDENCE**: 0.90\n**MECHANISM**: OCT2-mediated renal accumulation of Met exceeds mitochondrial buffering capacity (low GSH, spare respiratory capacity), while liver/muscle tolerate transient Complex I inhibition via adenylate kinase and creatine kinase.\n**FALSIFIABLE BY**: Toxicity in muscle at [Met] < renal cortex, or OCT2-knockout mice showing no renal toxicity.\n\n**CLAIM 3**: Supratherapeutic [Met] (>100 \u00b5M plasma) achieves >5 mM mitochondrial [Met], causing irreversible Complex I inhibition via kinetic trapping, PMF collapse, and ROS-mediated GSH depletion.\n**TYPE**: 2 (novel but plausible)\n**CONFIDENCE**: 0.82\n**MECHANISM**: At [Met] > IC\u2085\u2080 (~2\u201310 mM), Met binds Complex I irreversibly (kinetic trapping), NADH accumulation reverses malate-aspartate shuttle, and PMF collapse triggers lactate efflux via MCT1/4.\n**FALSIFIABLE BY**: Lactic acidosis at [Met] < IC\u2085\u2080 for Complex I, or lack of correlation between mitochondrial [Met] and toxicity.\n\n**CLAIM 4**: Metformin\u2019s dose-dependent effects are modulated by redox-sensitive feedback loops: low doses enhance mitophagy via AMPK-PINK1, while high doses deplete GSH, accelerating mitochondrial dysfunction.\n**TYPE**: 3 (speculative)\n**CONFIDENCE**: 0.65\n**MECHANISM**: AMPK-PINK1 axis promotes mitophagy at low [Met], but high [Met] depletes GSH, increasing ROS and inhibiting PINK1-mediated clearance.\n**FALSIFIABLE BY**: Metformin-treated cells with GSH supplementation showing no toxicity at high doses, or PINK1-knockout mice exhibiting no therapeutic effect.\n\n---\n\n**SECTION 3: UNKNOWNS**\n1. **Quantitative thresholds**: What are the exact mitochondrial [Met] thresholds for reversible vs. irreversible Complex I inhibition in vivo? (Missing: direct measurements in human tissues.)\n2. **Hill coefficients**: What are the Hill coefficients for AMPK activation and Complex I inhibition in primary human hepatocytes/renal cells? (Missing: tissue-specific kinetic data.)\n3. **Redox buffering**: How does GSH depletion kinetics correlate with PMF collapse and lactate production across tissues? (Missing: time-resolved redox imaging.)\n4. **Mitophagy dynamics**: Does AMPK-PINK1-mediated mitophagy precede or follow GSH depletion at toxic doses? (Missing: longitudinal studies.)\n\n---\n\n**SECTION 4: NEXT STEP**\n**Experiment**: Measure mitochondrial [Met], Complex I inhibition kinetics, and NADH/NAD\u207a ratios in OCT2-overexpressing vs. OCT2-knockout renal cells at 1\u2013100 \u00b5M Met, with simultaneous PMF and GSH monitoring.",
      "claims": [
        {
          "statement": "1**: The therapeutic window (1\u201310 \u00b5M plasma) is defined by AMPK\u2019s hypersensitive activation (20\u201340% \u0394AMP:ATP) at sub-toxic Complex I inhibition (~20\u201340% block), while lactic acidosis requires >50% irreversible Complex I inhibition (>5 mM mitochondrial [Met]). **TYPE**: 1 (converged + mechanistic) **CONFIDENCE**: 0.88 **MECHANISM**: AMPK\u2019s \u03b3-subunit binds AMP cooperatively (Hill coefficient >1), amplifying sensitivity to mild energetic stress, whereas Complex I inhibition follows non-cooperative kinetics (Hill coefficient ~1), requiring higher [Met] for toxicity. **FALSIFIABLE BY**: Evidence that AMPK activation requires >50% Complex I block, or that Hill coefficients for AMPK and Complex I are identical.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": AMPK\u2019s \u03b3-subunit binds AMP cooperatively (Hill coefficient >1), amplifying sensitivity to mild energetic stress, whereas Complex I inhibition follows non-cooperative kinetics (Hill coefficient ~1), requiring higher [Met] for toxicity.",
          "falsifiable_by": ": Evidence that AMPK activation requires >50% Complex I block, or that Hill coefficients for AMPK and Complex I are identical."
        },
        {
          "statement": "2**: Tissue-specific toxicity is determined by the product of OCT transporter density and mitochondrial reserve, with kidney (OCT2-high, low reserve) > liver (OCT1-high, moderate reserve) > muscle (low OCT, high reserve) vulnerability. **TYPE**: 1 (converged) **CONFIDENCE**: 0.90 **MECHANISM**: OCT2-mediated renal accumulation of Met exceeds mitochondrial buffering capacity (low GSH, spare respiratory capacity), while liver/muscle tolerate transient Complex I inhibition via adenylate kinase and creatine kinase. **FALSIFIABLE BY**: Toxicity in muscle at [Met] < renal cortex, or OCT2-knockout mice showing no renal toxicity.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": OCT2-mediated renal accumulation of Met exceeds mitochondrial buffering capacity (low GSH, spare respiratory capacity), while liver/muscle tolerate transient Complex I inhibition via adenylate kinase and creatine kinase.",
          "falsifiable_by": ": Toxicity in muscle at [Met] < renal cortex, or OCT2-knockout mice showing no renal toxicity."
        },
        {
          "statement": "3**: Supratherapeutic [Met] (>100 \u00b5M plasma) achieves >5 mM mitochondrial [Met], causing irreversible Complex I inhibition via kinetic trapping, PMF collapse, and ROS-mediated GSH depletion. **TYPE**: 2 (novel but plausible) **CONFIDENCE**: 0.82 **MECHANISM**: At [Met] > IC\u2085\u2080 (~2\u201310 mM), Met binds Complex I irreversibly (kinetic trapping), NADH accumulation reverses malate-aspartate shuttle, and PMF collapse triggers lactate efflux via MCT1/4. **FALSIFIABLE BY**: Lactic acidosis at [Met] < IC\u2085\u2080 for Complex I, or lack of correlation between mitochondrial [Met] and toxicity.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": At [Met] > IC\u2085\u2080 (~2\u201310 mM), Met binds Complex I irreversibly (kinetic trapping), NADH accumulation reverses malate-aspartate shuttle, and PMF collapse triggers lactate efflux via MCT1/4.",
          "falsifiable_by": ": Lactic acidosis at [Met] < IC\u2085\u2080 for Complex I, or lack of correlation between mitochondrial [Met] and toxicity."
        },
        {
          "statement": "4**: Metformin\u2019s dose-dependent effects are modulated by redox-sensitive feedback loops: low doses enhance mitophagy via AMPK-PINK1, while high doses deplete GSH, accelerating mitochondrial dysfunction. **TYPE**: 3 (speculative) **CONFIDENCE**: 0.65 **MECHANISM**: AMPK-PINK1 axis promotes mitophagy at low [Met], but high [Met] depletes GSH, increasing ROS and inhibiting PINK1-mediated clearance. **FALSIFIABLE BY**: Metformin-treated cells with GSH supplementation showing no toxicity at high doses, or PINK1-knockout mice exhibiting no therapeutic effect. ---",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": AMPK-PINK1 axis promotes mitophagy at low [Met], but high [Met] depletes GSH, increasing ROS and inhibiting PINK1-mediated clearance.",
          "falsifiable_by": ": Metformin-treated cells with GSH supplementation showing no toxicity at high doses, or PINK1-knockout mice exhibiting no therapeutic effect. --- **"
        }
      ]
    },
    {
      "model": "grok",
      "raw": "\u2500\u2500\u2500 SECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\nSub-questions:  \n1. What are the dose-dependent thresholds and kinetics for metformin-induced Complex I inhibition (IC50 ~2-10 mM mitochondrial [Met], Hill n\u22481) versus AMPK activation (threshold ~10-20% \u0394AMP/ATP, Hill n>1)?  \n2. How does mild (<50% Complex I inhibition) versus severe (>70%) inhibition shift outcomes from reversible energetic stress (AMPK\u2192benefit) to irreversible redox collapse (NADH\u2191, lactate efflux)?  \n3. How do tissue differences in OCT uptake (liver OCT1, kidney OCT2), mitochondrial accumulation (\u0394\u03c8-driven 500-1500x), and reserve (spare capacity: muscle> liver> kidney) determine toxicity onset?  \n\nKey variables/relationships: Plasma [Met] \u2192 OCT uptake \u2192 mito [Met] \u2192 %CI inhibition \u2192 \u0394AMP/ATP \u2192 AMPK (benefit if <50%) or ATP\u2193/NADH\u2191/lactate (poison if >70%); reserve buffers transient inhibition (State 3/4 ratio >5 tolerates 50% block).\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: Metformin's therapeutic benefit arises at plasma [Met] 10-50 \u00b5M (mito [Met] 5-25 mM), yielding 20-40% Complex I inhibition\u2014sufficient for AMPK activation (\u0394AMP/ATP 10-20%) but below toxicity threshold\u2014while supratherapeutic >100 \u00b5M (mito >50 mM) exceeds IC50 (2-10 mM), causing >70% inhibition, PMF collapse, and lactic acidosis.  \nTYPE: 1  \nCONFIDENCE: 0.92  \nMECHANISM: Mild inhibition increases AMP via adenylate kinase equilibrium shift, allosterically activating AMPK (cooperative Hill n=2-4); severe inhibition saturates buffering, elevates NADH/NAD+ >2:1, reversing shuttles and forcing lactate production.  \nFALSIFIABLE BY: AMPK activation or lactate rise at plasma [Met] yielding mito [Met] << IC50 (<1 mM), or no correlation between %CI inhibition and \u0394AMP/ATP in hepatocytes.\n\nCLAIM: Complex I inhibition by metformin is reversible at therapeutic doses (off-rate > cellular transit time, t1/2 <10 min) due to competitive kinetics (Hill n=1, Km ~5 mM), but becomes kinetically trapped/irreversible at supratherapeutic doses (>IC90), amplified by \u0394\u03c8-driven accumulation.  \nTYPE: 2  \nCONFIDENCE: 0.85  \nMECHANISM: Low [Met] allows rapid dissociation and spare capacity compensation; high [Met] exceeds buffering (AK/CK saturation), sustaining >70% block and ROS/GSH depletion.  \nFALSIFIABLE BY: Washout experiments showing persistent >50% CI inhibition after brief supratherapeutic exposure, absent in low-dose controls, or identical reversibility across doses.\n\nCLAIM: Tissue-specific outcomes follow reserve*OCT product: kidney (low reserve R=2-3, high OCT2) most vulnerable (toxicity at plasma 100 \u00b5M), liver (R=4-5, high OCT1) intermediate (therapeutic target), muscle (R>10, low OCT) resistant\u2014explaining lactic acidosis onset in kidney>liver.  \nTYPE: 1  \nCONFIDENCE: 0.89  \nMECHANISM: High OCT drives mito [Met]; low reserve fails to upregulate uncoupling/backup glycolysis, leading to ATP<30% and necrosis in kidney vs. AMPK/mitophagy in muscle.  \nFALSIFIABLE BY: Equivalent toxicity in OCT-knockout kidney or reserve-enhanced (e.g., PGC1\u03b1 OE) kidney at [Met] toxic to WT liver.\n\nCLAIM: AMPK hypersensitivity (threshold 10% \u0394AMP/ATP, Hill n>2) vs. Complex I non-cooperativity (n=1) creates 10-fold therapeutic index (benefit at 20% block, toxicity >70%), constrained by FDA minimum TI=10.  \nTYPE: 2  \nCONFIDENCE: 0.82  \nMECHANISM: Cooperative AMP-binding amplifies mild energetic signals to AMPK without requiring strong CI block; steep toxicity sigmoid demands >IC90.  \nFALSIFIABLE BY: Hill n\u22641 for AMPK in metformin-treated cells, or TI<10 in dose-response data.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\nPrecise in vivo mito:plasma accumulation ratios per tissue (lit: 500-1500x varies by \u0394\u03c8/OCT). Kinetic constants (kon/koff for CI binding; t1/2 irreversibility). Quantitative reserve metrics (% spare capacity at 50% CI block: liver=40%, kidney=20%?). Threshold %CI inhibition for in vivo lactate>5 mM in humans. Redox loop details (GSH EC50 for metformin-ROS).\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nIsolated mito from human liver/kidney/muscle: dose-response [Met] 1-100 mM for CI activity, ATP/lactate, reversibility (washout), vs. AMPK in intact cells.",
      "claims": [
        {
          "statement": "Metformin's therapeutic benefit arises at plasma [Met] 10-50 \u00b5M (mito [Met] 5-25 mM), yielding 20-40% Complex I inhibition\u2014sufficient for AMPK activation (\u0394AMP/ATP 10-20%) but below toxicity threshold\u2014while supratherapeutic >100 \u00b5M (mito >50 mM) exceeds IC50 (2-10 mM), causing >70% inhibition, PMF collapse, and lactic acidosis.",
          "type": 1,
          "confidence": 0.92,
          "mechanism": "Mild inhibition increases AMP via adenylate kinase equilibrium shift, allosterically activating AMPK (cooperative Hill n=2-4); severe inhibition saturates buffering, elevates NADH/NAD+ >2:1, reversing shuttles and forcing lactate production.",
          "falsifiable_by": "AMPK activation or lactate rise at plasma [Met] yielding mito [Met] << IC50 (<1 mM), or no correlation between %CI inhibition and \u0394AMP/ATP in hepatocytes."
        },
        {
          "statement": "Complex I inhibition by metformin is reversible at therapeutic doses (off-rate > cellular transit time, t1/2 <10 min) due to competitive kinetics (Hill n=1, Km ~5 mM), but becomes kinetically trapped/irreversible at supratherapeutic doses (>IC90), amplified by \u0394\u03c8-driven accumulation.",
          "type": 2,
          "confidence": 0.85,
          "mechanism": "Low [Met] allows rapid dissociation and spare capacity compensation; high [Met] exceeds buffering (AK/CK saturation), sustaining >70% block and ROS/GSH depletion.",
          "falsifiable_by": "Washout experiments showing persistent >50% CI inhibition after brief supratherapeutic exposure, absent in low-dose controls, or identical reversibility across doses."
        },
        {
          "statement": "Tissue-specific outcomes follow reserve*OCT product: kidney (low reserve R=2-3, high OCT2) most vulnerable (toxicity at plasma 100 \u00b5M), liver (R=4-5, high OCT1) intermediate (therapeutic target), muscle (R>10, low OCT) resistant\u2014explaining lactic acidosis onset in kidney>liver.",
          "type": 1,
          "confidence": 0.89,
          "mechanism": "High OCT drives mito [Met]; low reserve fails to upregulate uncoupling/backup glycolysis, leading to ATP<30% and necrosis in kidney vs. AMPK/mitophagy in muscle.",
          "falsifiable_by": "Equivalent toxicity in OCT-knockout kidney or reserve-enhanced (e.g., PGC1\u03b1 OE) kidney at [Met] toxic to WT liver."
        },
        {
          "statement": "AMPK hypersensitivity (threshold 10% \u0394AMP/ATP, Hill n>2) vs. Complex I non-cooperativity (n=1) creates 10-fold therapeutic index (benefit at 20% block, toxicity >70%), constrained by FDA minimum TI=10.",
          "type": 2,
          "confidence": 0.82,
          "mechanism": "Cooperative AMP-binding amplifies mild energetic signals to AMPK without requiring strong CI block; steep toxicity sigmoid demands >IC90.",
          "falsifiable_by": "Hill n\u22641 for AMPK in metformin-treated cells, or TI<10 in dose-response data. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "gemini",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] At supratherapeutic doses (>100 \u00b5M plasma), metformin's action shifts from an optimizer to a poison due to the saturation of mitochondrial buffering systems (adenylate kinase, creatine kinase) and the onset of redox stress (NADH/NAD+ imbalance), making the inhibition of Complex I irreversible within the relevant cellular timescale.\n    MECHANISM: High intramitochondrial [Met] causes durable Complex I block, leading to NADH accumulation, reversal of the malate-aspartate shuttle, and forced glycolysis with lactate production; depleted ATP compromises cellular ion homeostasis, culminating in necrosis.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.818\n\n  [REPLICATED] 4:** Tissue vulnerability to metformin toxicity follows an **inverse relationship with mitochondrial reserve** and a **direct relationship with OCT transporter density**, with liver (OCT1-high, moderate reserve) as the primary therapeutic target and first toxicity site, and kidney (OCT2-high, low reserve) as the secondary toxicity site. - **TYPE:** 1 (converged; mechanistic support) - **CONFIDENCE:** 0.88 - **MECHANISM:** Liver and muscle (high reserve) buffer transient Complex I inhibition via spare respiratory capacity, while renal cortex (low reserve, high OCT2) accumulates toxic [Met] and lacks redox buffering (low GSH). - **FALSIFIABLE BY:** Toxicity in high-reserve tissues (e.g., muscle) at [Met] lower than renal cortex, or lack of OCT2-mediated uptake in renal toxicity.\n    MECHANISM: Liver and muscle (high reserve) buffer transient Complex I inhibition via spare respiratory capacity, while renal cortex (low reserve, high OCT2) accumulates toxic [Met] and lacks redox buffering (low GSH). - **FALSIFIABLE BY:** Toxicity in high-reserve tissues (e.g., muscle) at [Met] lower than renal cortex, or lack of OCT2-mediated uptake in renal toxicity.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.86\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] The switch from metabolic benefit to toxicity is a threshold event determined by the degree of Complex I inhibition crossing ~50%, a point at which compensatory glycolysis and lactate production can no longer maintain cellular ATP homeostasis.\n    SOURCE: gemini | CONFIDENCE: 0.95\n  [SINGULAR] 2:** Supratherapeutic metformin (>100 \u00b5M plasma) achieves **mitochondrial [Met] >5 mM**, exceeding Complex I IC50 (~2\u201310 mM) and causing >50% block, leading to PMF collapse, ATP depletion, and lactic acidosis\u2014amplified in tissues with low mitochondrial reserve (renal cortex) or high OCT2 expression. - **TYPE:** 2 (novel but mechanistically plausible; singular thread validation) - **CONFIDENCE:** 0.85 - **MECHANISM:** At [Met] >5 mM, Complex I inhibition becomes irreversible (kinetic trapping), ROS production overwhelms antioxidant defenses (GSH depletion), and PMF collapse triggers lactate efflux via MCT1/4. - **FALSIFIABLE BY:** Data showing lactic acidosis at [Met] < IC50 for Complex I, or lack of correlation between OCT2 expression and renal toxicity.\n    SOURCE: mistral | CONFIDENCE: 0.85\n  [SINGULAR] The therapeutic window (1-10 \u00b5M plasma) exists because AMPK activation is a sensitive, low-amplitude readout of a mild energetic perturbation (e.g., 10-30% Complex I inhibition), while lactic acidosis requires a sustained, high-grade inhibition (>70%) that collapses the proton motive force in vulnerable tissues.\n    SOURCE: deepseek | CONFIDENCE: 0.85\n  [SINGULAR] 3:** AMPK activation threshold (~20% \u0394AMP:ATP) is **allosterically hypersensitive** compared to Complex I inhibition, enabling therapeutic effects at [Met] where inhibition is sub-toxic (~20\u201340% block). - **TYPE:** 2 (singular thread; requires validation) - **CONFIDENCE:** 0.80 - **MECHANISM:** AMPK\u2019s \u03b3-subunit binds AMP cooperatively (Hill coefficient >1), amplifying sensitivity to small \u0394AMP:ATP, while Complex I inhibition follows non-cooperative kinetics (Hill coefficient ~1). - **FALSIFIABLE BY:** Evidence that AMPK activation requires >50% Complex I block, or that Hill coefficients for AMPK activation and Complex I inhibition are identical.\n    SOURCE: mistral | CONFIDENCE: 0.8\n  [SINGULAR] Tissue vulnerability hierarchy is kidney (OCT2-high, low reserve) > liver (OCT1-high, moderate reserve) > muscle (low OCT, high reserve), explaining why lactic acidosis originates primarily from hepatic lactate clearance failure while renal accumulation drives toxicity in renal impairment.\n    SOURCE: claude | CONFIDENCE: 0.78\n  [SINGULAR] 5:** Metformin\u2019s dose-dependent effects are modulated by **redox-sensitive feedback loops**: low doses enhance mitophagy via AMPK-PINK1, while high doses deplete GSH, accelerating mitochondrial dysfunction. - **TYPE:** 3 (speculative; singular thread) - **CONFIDENCE:** 0.65 - **MECHANISM:** AMPK-PINK1 axis promotes mitophagy at low [Met], but high [\n    SOURCE: mistral | CONFIDENCE: 0.65\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 41% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\n\u2500\u2500\u2500\nSECTION 1: DECOMPOSITION (max 200 tokens)\n\n1.  **Kinetic Divergence:** What are the quantitative differences in the dose-response curves for AMPK activation versus Complex I inhibition, and how do these kinetics (e.g., Hill coefficients, EC50/IC50) create the therapeutic window?\n2.  **Bioenergetic Thresholding:** How does a cell's mitochondrial reserve capacity define a specific threshold of Complex I inhibition (~50-70%) beyond which ATP homeostasis fails, triggering a non-linear switch from metabolic adaptation to catastrophic lactic acidosis?\n3.  **Tissue-Specific Failure:** How do tissue-specific metformin concentrations, dictated by OCT transporter expression, interact with intrinsic mitochondrial reserve to determine the hierarchy of organ vulnerability (kidney > liver > muscle)?\n\nKey variables: Intramitochondrial [Metformin], % Complex I inhibition, AMP:ATP ratio, mitochondrial reserve (spare respiratory capacity), OCT transporter density. The core relationship is how [Metformin] drives divergent, non-linear cellular outcomes based on tissue-specific bioenergetic buffering.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\n\nCLAIM: The therapeutic window is created by kinetic hypersensitivity of AMPK; its cooperative activation (Hill coefficient > 1.5) robustly transduces mild energetic stress (10-30% Complex I inhibition) that is non-cooperative (Hill coefficient \u2248 1.0) and sub-toxic.\nTYPE: 1\nCONFIDENCE: 0.90\nMECHANISM: This kinetic separation allows a low metformin dose to generate a strong downstream metabolic signal (AMPK) while causing only a mild, easily buffered perturbation of mitochondrial respiration.\nFALSIFIABLE BY: Direct measurement showing that the in-situ Hill coefficient for AMPK activation in response to metformin is \u2264 1.0, or that significant AMPK activation requires >50% Complex I inhibition.\n\nCLAIM: The switch to toxicity is a sharp threshold event, not a continuum, occurring when Complex I inhibition surpasses a tissue's specific bioenergetic \"tipping point\" (estimated at 60-70% inhibition), a point determined by its mitochondrial reserve.\nTYPE: 1\nCONFIDENCE: 0.85\nMECHANISM: Below this threshold, cells compensate via spare respiratory capacity and glycolysis; above it, the proton-motive force collapses, ATP synthesis fails catastrophically, and lactate production overwhelms cellular buffering and clearance.\nFALSIFIABLE BY: Evidence of a linear, graded increase in lactate production with metformin dose, rather than a sharp, non-linear inflection point correlated with a specific degree of Complex I inhibition.\n\nCLAIM: At supratherapeutic doses, extreme NADH/NAD+ accumulation (>10-fold increase) secondarily inhibits pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (\u03b1KGDH), creating a \"redox lock\" that shunts all available glucose to lactate, independent of direct Complex I action.\nTYPE: 2\nCONFIDENCE: 0.75\nMECHANISM: This downstream redox stress, a consequence of severe Complex I blockade, is the proximate cause of fulminant lactic acidosis and makes the toxic state difficult to reverse.\nFALSIFIABLE BY: Demonstrating that restoring Complex I activity in metformin-toxic cells fails to normalize the NADH/NAD+ ratio or reduce lactate production.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\n\n1.  The precise intramitochondrial concentration of metformin in human hepatocytes, renal proximal tubule cells, and skeletal myocytes at both therapeutic (1-10 \u00b5M plasma) and toxic (>100 \u00b5M plasma) levels. This is the most critical missing variable.\n2.  The in-vivo IC50 for metformin against Complex I within the mitochondrial matrix, which may differ from in-vitro estimates due to membrane potential and local environment.\n3.  Quantitative data on the spare respiratory capacity (mitochondrial reserve) of human renal cortical tissue, which is hypothesized to be low but is not well-characterized compared to liver or muscle.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\n\nPerform positron emission tomography (PET) imaging with [11C]metformin in a large animal model (e.g., pig) during euglycemic clamp to quantify tissue-specific and, if resolution permits, subcellular metformin accumulation across a range of therapeutic to toxic infusions.",
      "claims": [
        {
          "statement": "The therapeutic window is created by kinetic hypersensitivity of AMPK; its cooperative activation (Hill coefficient > 1.5) robustly transduces mild energetic stress (10-30% Complex I inhibition) that is non-cooperative (Hill coefficient \u2248 1.0) and sub-toxic.",
          "type": 1,
          "confidence": 0.9,
          "mechanism": "This kinetic separation allows a low metformin dose to generate a strong downstream metabolic signal (AMPK) while causing only a mild, easily buffered perturbation of mitochondrial respiration.",
          "falsifiable_by": "Direct measurement showing that the in-situ Hill coefficient for AMPK activation in response to metformin is \u2264 1.0, or that significant AMPK activation requires >50% Complex I inhibition."
        },
        {
          "statement": "The switch to toxicity is a sharp threshold event, not a continuum, occurring when Complex I inhibition surpasses a tissue's specific bioenergetic \"tipping point\" (estimated at 60-70% inhibition), a point determined by its mitochondrial reserve.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Below this threshold, cells compensate via spare respiratory capacity and glycolysis; above it, the proton-motive force collapses, ATP synthesis fails catastrophically, and lactate production overwhelms cellular buffering and clearance.",
          "falsifiable_by": "Evidence of a linear, graded increase in lactate production with metformin dose, rather than a sharp, non-linear inflection point correlated with a specific degree of Complex I inhibition."
        },
        {
          "statement": "At supratherapeutic doses, extreme NADH/NAD+ accumulation (>10-fold increase) secondarily inhibits pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (\u03b1KGDH), creating a \"redox lock\" that shunts all available glucose to lactate, independent of direct Complex I action.",
          "type": 2,
          "confidence": 0.75,
          "mechanism": "This downstream redox stress, a consequence of severe Complex I blockade, is the proximate cause of fulminant lactic acidosis and makes the toxic state difficult to reverse.",
          "falsifiable_by": "Demonstrating that restoring Complex I activity in metformin-toxic cells fails to normalize the NADH/NAD+ ratio or reduce lactate production. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "deepseek",
      "raw": "\u2500\u2500\u2500 \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\n[I have reviewed the provided consensus and singular threads. I will build upon the converged claims and investigate the singular threads, particularly the quantitative thresholds and kinetic models.]\n\nSECTION 1: DECOMPOSITION\n1.  **Kinetic Thresholds:** What are the quantitative relationships between plasma [Met], mitochondrial [Met], Complex I inhibition (% block), and AMPK activation?\n2.  **Tissue-Specific Determinants:** How do OCT transporter kinetics, mitochondrial reserve capacity, and baseline redox state (e.g., GSH levels) interact to set tissue-specific toxicity thresholds?\n3.  **Systemic Tipping Point:** What is the mechanistic link between cellular ATP depletion in specific tissues (liver, kidney) and the systemic shift to lactic acidosis (failure of lactate clearance vs. overproduction)?\n4.  **Temporal Dynamics:** Is the shift from benefit to toxicity a function of concentration alone, or does duration of exposure at a given concentration create kinetic trapping in mitochondrial dysfunction?\n\nKey Variables: Plasma [Met], OCT1/2 Vmax/Km, intramitochondrial [Met], Complex I IC50 & Hill coefficient, spare respiratory capacity (SRC), AMPK activation EC50 & Hill coefficient, hepatic lactate clearance rate.\n\nSECTION 2: CLAIMS\nCLAIM 1: The therapeutic-to-toxic transition occurs at a mitochondrial [Met] of ~1-5 mM, which corresponds to ~40-60% Complex I inhibition. This range sits between the EC50 for AMPK-mediated benefits (~20-30% inhibition) and the threshold for irreversible PMF collapse (>70% inhibition).\nTYPE: 1 (converged; quantitative refinement)\nCONFIDENCE: 0.82\nMECHANISM: AMPK activation (cooperative, high-sensitivity) is maximal at sub-toxic inhibition, while ATP synthase rate declines linearly with PMF; a >50% PMF drop crosses the minimum threshold for maintaining cellular ion pumps.\nFALSIFIABLE BY: Data showing maximal AMPK activation requires >60% Complex I block, or that PMF is maintained with >80% sustained inhibition.\n\nCLAIM 2: Renal toxicity precedes and drives systemic lactic acidosis in overdose by creating a \"lactate sink\": proximal tubule necrosis (due to low mitochondrial reserve) releases lactate and KIM-1, impairing remaining renal function and reducing systemic lactate clearance, which then overwhelms hepatic capacity.\nTYPE: 2 (novel synthesis of converged threads)\nCONFIDENCE: 0.75\nMECHANISM: High OCT2-mediated uptake and low SRC cause rapid ATP depletion and necrosis in renal cortex; released lactate and tubular damage reduce renal lactate/metformin excretion, causing [lactate] to rise until hepatic Cori cycle capacity is saturated.\nFALSIFIABLE BY: Animal model showing lactic acidosis onset prior to significant rise in serum creatinine or KIM-1, or unchanged lactate kinetics in nephrectomized overdose models.\n\nCLAIM 3: The \"irreversibility\" of supratherapeutic Complex I inhibition is not purely competitive but involves time-dependent, redox-mediated damage to Complex I subunits (e.g., glutathionylation of the 75 kDa subunit), making recovery dependent on GSH pool and protein turnover rates.\nTYPE: 2 (investigating singular thread #5)\nCONFIDENCE: 0.70\nMECHANISM: Sustained high [Met] increases mitochondrial ROS, oxidizing the Complex I flavoprotein site; depleted GSH pools permit irreversible sulfenic acid formation, locking the enzyme in an inactive state until repaired or replaced.\nFALSIFIABLE BY: Mass spectrometry showing no metformin-induced covalent modifications of Complex I, or toxicity being fully rescued by immediate washout even after 60 min exposure at >10 mM [Met].\n\nSECTION 3: UNKNOWNS\n1.  The exact Hill coefficient for AMPK activation by metformin-induced AMP/ADP rise in hepatocytes in vivo. Is it >1.5 (highly cooperative) or ~1 (linear)?\n2.  The quantitative \"spare respiratory capacity\" of human renal proximal tubule cells versus hepatocytes. A <20% SRC in tubules would make them exquisitely sensitive.\n3.  The pharmacokinetic link between plasma [Met] and mitochondrial matrix [Met] as a function of OCT activity and mitochondrial membrane potential. We lack this conversion factor.\n4.  Whether metformin-induced lactic acidosis in patients with renal impairment is primarily due to accumulated metformin or to the underlying renal disease's compromise of lactate clearance.\n\nSECTION 4: NEXT STEP\nMeasure, in parallel, the Hill coefficients for AMPK activation (p-ACC signal) and OCR inhibition in primary human hepatocytes and renal proximal tubule cells across a high-resolution metformin concentration range (0.1 \u00b5M \u2013 30 mM) to define the precise therapeutic-toxic kinetic divergence.",
      "claims": [
        {
          "statement": "1: The therapeutic-to-toxic transition occurs at a mitochondrial [Met] of ~1-5 mM, which corresponds to ~40-60% Complex I inhibition. This range sits between the EC50 for AMPK-mediated benefits (~20-30% inhibition) and the threshold for irreversible PMF collapse (>70% inhibition).",
          "type": 1,
          "confidence": 0.82,
          "mechanism": "AMPK activation (cooperative, high-sensitivity) is maximal at sub-toxic inhibition, while ATP synthase rate declines linearly with PMF; a >50% PMF drop crosses the minimum threshold for maintaining cellular ion pumps.",
          "falsifiable_by": "Data showing maximal AMPK activation requires >60% Complex I block, or that PMF is maintained with >80% sustained inhibition."
        },
        {
          "statement": "2: Renal toxicity precedes and drives systemic lactic acidosis in overdose by creating a \"lactate sink\": proximal tubule necrosis (due to low mitochondrial reserve) releases lactate and KIM-1, impairing remaining renal function and reducing systemic lactate clearance, which then overwhelms hepatic capacity.",
          "type": 2,
          "confidence": 0.75,
          "mechanism": "High OCT2-mediated uptake and low SRC cause rapid ATP depletion and necrosis in renal cortex; released lactate and tubular damage reduce renal lactate/metformin excretion, causing [lactate] to rise until hepatic Cori cycle capacity is saturated.",
          "falsifiable_by": "Animal model showing lactic acidosis onset prior to significant rise in serum creatinine or KIM-1, or unchanged lactate kinetics in nephrectomized overdose models."
        },
        {
          "statement": "3: The \"irreversibility\" of supratherapeutic Complex I inhibition is not purely competitive but involves time-dependent, redox-mediated damage to Complex I subunits (e.g., glutathionylation of the 75 kDa subunit), making recovery dependent on GSH pool and protein turnover rates.",
          "type": 2,
          "confidence": 0.7,
          "mechanism": "Sustained high [Met] increases mitochondrial ROS, oxidizing the Complex I flavoprotein site; depleted GSH pools permit irreversible sulfenic acid formation, locking the enzyme in an inactive state until repaired or replaced.",
          "falsifiable_by": "Mass spectrometry showing no metformin-induced covalent modifications of Complex I, or toxicity being fully rescued by immediate washout even after 60 min exposure at >10 mM [Met]."
        }
      ]
    }
  ],
  "snapshot": {
    "round_num": 0,
    "jaccard": 0.02644327350209703,
    "cosine": 0.6974595606327056,
    "jsd": 0.09961676960656957,
    "kappa": 0.8935185185185185,
    "type_distribution": {
      "0": 0.0,
      "1": 0.3888888888888889,
      "2": 0.6111111111111112,
      "3": 0.0
    },
    "type_01_ratio": 0.3888888888888889,
    "n_claims_per_model": [
      4,
      4,
      4,
      3,
      3
    ]
  },
  "total_calls": 5
}